IMPROVEDD Risk Score for Venous Thromboembolism (VTE)

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Very Low Risk0–0
  • Low Risk1–1
  • Moderate Risk2–2
  • Moderate-High Risk3–3
Direct Clinical Answer

The IMPROVEDD Risk Score for Venous Thromboembolism (VTE) calculator is designed for bedside predicting 77-day risk of acute venous thromboembolism (VTE) in hospitalized medical patients by incorporating D-dimer levels into the IMPROVE Risk Score in clinical practice. The resulting score directly guides clinician decision-making regarding.

Clinical Guidelines & Evidence

Predicts 77-day risk of acute venous thromboembolism (VTE) in hospitalized medical patients by incorporating D-dimer levels into the IMPROVE Risk Score. The IMPROVEDD (IMPROVE + D-dimer) score enhances the original IMPROVE VTE risk assessment by adding D-dimer ≥2× upper limit of normal as an additional risk factor worth 2 points. This validated clinical prediction tool was developed from the APEX trial involving 7,441 hospitalized medically ill patients. The addition of D-dimer significantly improves VTE risk discrimination and reclassification compared to the original IMPROVE score. An IMPROVEDD score ≥2 identifies patients with heightened VTE risk through 77 days, helping clinicians make more informed decisions about extended thromboprophylaxis duration in acutely ill medical patients.

Clinical Indication

The IMPROVEDD Risk Score for Venous Thromboembolism (VTE) is indicated for bedside clinical practice to support Predicts 77-day risk of acute venous thromboembolism (VTE) in hospitalized medical patients by incorporating D-dimer levels into the IMPROVE Risk Score. The IMPROVEDD (IMPROVE + D-dimer) score enhances the original IMPROVE VTE risk assessment by adding D-dimer ≥2× upper limit of normal as an additional risk factor worth 2 points. This validated clinical prediction tool was developed from the APEX trial involving 7,441 hospitalized medically ill patients. The addition of D-dimer significantly improves VTE risk discrimination and reclassification compared to the original IMPROVE score. An IMPROVEDD score ≥2 identifies patients with heightened VTE risk through 77 days, helping clinicians make more informed decisions about extended thromboprophylaxis duration in acutely ill medical patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.

Formula & Variables:

Score = Previous VTE (3) + Known thrombophilia (2) + Current lower-limb paralysis (2) + Current cancer (2) + Immobilized ≥7 days (1) + ICU/CCU stay (1) + Age >60 years (1) + D-dimer ≥2×ULN (2)

Input Parameters

NameTypeRequiredDescription
previous_vtestringYesHistory of previous venous thromboembolism (deep vein thrombosis or pulmonary embolism). Previous VTE is the strongest risk factor, carrying the highest point value (3 points) due to significantly increased likelihood of recurrence
known_thrombophiliastringYesKnown thrombophilia or hereditary thrombotic disorder (Factor V Leiden, prothrombin gene mutation, antithrombin deficiency, protein C or S deficiency, antiphospholipid syndrome). Thrombophilic disorders increase VTE risk through various mechanisms affecting coagulation pathways
current_lower_limb_paralysisstringYesCurrent lower-limb paralysis or paresis affecting mobility. Paralysis increases VTE risk through venous stasis and reduced muscle pump function in affected limbs, particularly concerning for DVT development
current_cancerstringYesCurrent active cancer diagnosis regardless of type or stage. Cancer increases VTE risk through multiple mechanisms including tumor-related procoagulant factors, chemotherapy effects, reduced mobility, and systemic hypercoagulable state
immobilized_7_daysstringYesImmobilized ≥7 days immediately prior to and during hospital admission. Prolonged immobilization increases VTE risk through venous stasis and activation of coagulation pathways. Includes bed rest, wheelchair confinement, or significant mobility limitation
icu_ccu_staystringYesCurrent stay in intensive care unit (ICU) or coronary care unit (CCU). Critical care setting indicates severe illness with increased VTE risk from immobility, invasive procedures, systemic inflammation, and hemodynamic instability
age_over_60stringYesAge greater than 60 years. Advanced age increases VTE risk through age-related changes in coagulation factors, decreased mobility, increased comorbidities, and reduced physiological reserve
d_dimer_elevatedstringYesD-dimer ≥2× upper limit of normal (ULN). Elevated D-dimer reflects ongoing fibrin formation and breakdown, indicating activation of the coagulation and fibrinolytic systems. This biomarker significantly enhances VTE risk prediction when added to clinical risk factors

Score Interpretation & Guidance

RangeStageDescription
0–0Very Low RiskScore 0 points
1–1Low RiskScore 1 point
2–2Moderate RiskScore 2 points
3–3Moderate-High RiskScore 3 points
4–4High RiskScore 4 points
5–14Very High RiskScore 5-14 points

Evidence-Based References (EBM)

  • Gibson CM, Spyropoulos AC, Cohen AT, et al. The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. TH Open. 2017 Oct 9;1(1):e56-e65. doi: 10.1055/s-0037-1603929.DOI: 10.1055/s-0037-1603929
  • Spyropoulos AC, Lipardi C, Xu J, et al. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. TH Open. 2020 Mar 6;4(1):e59-e65. doi: 10.1055/s-0040-1705137.DOI: 10.1055/s-0040-1705137
  • Spyropoulos AC, Anderson FA Jr, FitzGerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep;140(3):706-714. doi: 10.1378/chest.10-1944.DOI: 10.1378/chest.10-1944

Related calculators